Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipitor for chronic GVHD prevention in stem cell transplant
NCT03066466Phase 3
Key facts
- Status
- Withdrawn
- Start
- Dec 2019
- Primary completion
- Feb 2020
- Countries
- 1
- Sponsor
- Loyola University Chicago
- Drugs
- Atorva
- Conditions
- chronic graft-versus-host disease (cGVHD)
01
Overview
Phase 3, randomised, open-label trial of Atorva in chronic graft-versus-host disease (cGVHD), sponsored by Loyola University Chicago. Planned start Dec 2019; status: withdrawn.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Patients aged 18-65 with AML, ALL, or MDS undergoing matched unrelated donor stem cell transplant with adequate organ function and performance status.
04
Registry description
Chronic Graft Versus Host Disease (GVHD) is one of the most challenging complications in long term survivors of allogeneic stem cell transplantation. As the number of allogeneic stem cell transplantations rises annually, the incidence of chronic GVHD rates have also increased due to a variety of factors including but not limited to increasing use of peripheral blood stem cell (PBSC) grafts, increasing age of both donors and recipients, and increased use of matched unrelated donors. One study showed much lower than traditional acute GHVD rate and chronic GHVD which is similar with historical…
Beyond the preview
Go deeper on NCT03066466.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03066466.